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S U M M A R Y
Objectives: Hypergammaglobulinemia is one of the manifestations of B-cell dysfunction associated with
untreated HIV infection. Globulin levels are not routinely measured in HIV-infected patients on
treatment. The purpose of this study was to evaluate the effect of highly active antiretroviral therapy
(HAART) on calculated globulin levels.
Methods: The study group consisted of 75 HIV-infected treatment-naı¨ve patients, starting HAART, and
virologically suppressed for 6 months; 16 patients (21%) were HIV–HCV-co-infected.
Results: All patients experienced signiﬁcant increases in CD4 cell counts at 6 and 12months after HAART
initiation compared to baseline (p < 0.01 for all comparisons). The increase in CD4 cell counts was
signiﬁcant regardless of the HCV infection status. Signiﬁcant increases in albumin levels (p < 0.05 at 6
and 12 months), reductions in total protein (p < 0.01 at 1 year; not signiﬁcant at 6 months), and
concomitant signiﬁcant reductions in the calculated globulin levels (p < 0.001 at 6 and 12 months) after
HAART initiation compared to baseline were observed for the whole group. However, less than half the
patients achieved a normal albumin/globulin ratio at 1 year. HIV-monoinfected patients had signiﬁcant
changes in albumin, total protein, and calculated globulin levels. In contrast, HIV–HCV-co-infected
patients only showed signiﬁcant increases in albumin levels.
Conclusions: Future studies to evaluate the potential use of calculated globulin levels and albumin/
globulin ratios as readily available surrogate markers of B-cell immune reconstitution in HIV-
monoinfected patients are warranted.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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HIV infection affects all major lymphocyte populations,
including B-cells, natural killer (NK) cells, and CD4+ and CD8+
T-cells.1 Most of these HIV-associated abnormalities are thought to
be indirect effects of viral replication and to be mediated through
HIV-induced immune activation. Abnormalities in B-cell function
include hypergammaglobulinemia, polyclonal B-cell hyperactivity,
and poor responsiveness to neoantigens in vivo and B-cell stimuli
in vitro.2 Evidence of immune reconstitution of the T-cell
compartment occurs rapidly after initiation of highly active
antiretroviral therapy (HAART) and is correlated with decreased
morbidity andmortality.3 HAART also induces improvement in the§ Preliminary data were presented as a poster at the Annual Alliance for Graduate
Education and the Professoriate-Houston Louis Stokes Alliance for Minority
Participation (AGEP-HLSAMP) Research Day, April 29, 2008 at the University of
Houston, Texas, USA.
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doi:10.1016/j.ijid.2009.10.007manifestations of B-cell immune dysregulation, including reduc-
tion in polyclonal activation as measured by immunoglobulin
levels,4,5 reduction in markers of B-cell immune activation,6 and
normalization of B-cell count and B-cell subpopulation distribu-
tion.1 While the T-cell compartment reconstitution is monitored
routinely in clinical practice in patients started on HAART, B-cell
immune reconstitution is not. However, our ability to assess B-cell
reconstitution may have clinical implications, i.e., providing
guidance on the best timing for immunizations in this patient
population.7,8
Protein and albumin determinations are frequently included in
the routine laboratory evaluation of HIV-infected patients.
Albumin comprises 45–55% of the total serum protein. The serum
globulins are comprised of alpha-1 (10%), alpha-2 (30%), beta (34%)
and gamma (46%) globulins. Globulin levels can be indirectly
measured by a simple formula: globulin = total protein minus
albumin. We propose that calculated globulin levels decrease in
patients who achieve controlled viremia after starting HAART, and
hence, they could be utilized as a surrogate marker of improved
hypergammaglobulinemia and B-cell dysfunction.nal Society for Infectious Diseases.
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This was a retrospective chart review study of patients enrolled
in the HIV outpatient clinic at the Michael E. DeBakey VAMC. HIV-
infected patients, naı¨ve to treatment and started on HAART in the
period 2001–2005were eligible. To be included, patients needed to
have laboratory results within 3 months prior to starting HAART,
and at least every 6months thereafter, have12months of follow-
up, and have a viral load below the level of detection (<400 RNA
copies/ml) at 1 year after starting HAART and for 6 months. The
electronic and paper records of patients who met the inclusion
criteria were reviewed and abstracted using a standardized form.
Laboratory data included HIV-1 viral load, CD4 cell count, and total
protein and albumin levels at baseline (pre-HAART) and at 6 and 12
months after starting treatment. The normal ranges for total
protein and albuminwere those speciﬁed by the laboratory service
package (6.3–8.2 and 3.4–5 g/dl, respectively). Globulin was
calculated by subtracting albumin from total protein levels. An
albumin/globulin ratio >1 was considered normal. Because
patients with hepatitis C virus (HCV) infection and renal disease
may have elevated total protein levels, we assessed HCV status and
renal function. Patients were considered to be HCV-infected if they
had a positive HCV antibody test at any time that was conﬁrmed
with a qualitative or quantitative PCR. Patients were excluded if
calculated creatinine clearance, determined by the MDRD (Modi-
ﬁcation of Diet in Renal Disease) equation, was <60 ml/min.
3. Statistical analysis
A descriptive analysis of demographic and laboratory values
was initially done. Laboratory values at 6 months and 1 year after
HAART were compared with baseline levels by paired Student’s t-
test. The proportion of patients with normal laboratory values was
compared before and after HAART by McNemar test. Increases in
CD4 counts were correlatedwith increases in albumin or decreases
in total protein or calculated globulin by linear correlation and
calculation of Pearson’s coefﬁcient. Comparisons according to HCV
co-infection status were done by unpaired Student’s t-test.
Statistical analysis was performed with Intercooled Stata 9.2 for
Windows (College Station, TX, USA).
This study was approved by the Baylor College of Medicine
Institutional Review Board.
4. Results
Two hundred twenty-four presumed treatment-naı¨ve patients
were identiﬁed in our clinic database during the speciﬁed study
period. Of these, 75 patients were conﬁrmed treatment-naı¨ve after
careful review of electronic medical records, started HAART, ﬁt all
pre-speciﬁed inclusion criteria, andwere included in the ﬁnal study
sample. Reasons for exclusion included: prior antiretroviral
treatment, lack of laboratory results for the pre-speciﬁed time
periods (baseline, 6-month and 12-month), lack of hepatitis C
conﬁrmatory results, interruptions in antiretroviral treatment, and/
or viral rebound. The mean age for the study group was 48 11
years; 31% of patients were white, 61% were black, and 8% were
Hispanic. The demographics of the study groupwere similar to those of
the overall clinic population. The mean baseline CD4 cell count was
174  154 cells/mm3, total protein was 7.91 1.22 g/dl, and albumin
was 3.13  0.78 g/dl. Sixteen patients (21%) were HIV–HCV-co-
infected. Baseline CD4 cell count (177  152 vs. 163 160 cells/
mm3), total protein (7.84  1.11 vs. 8.18  1.58 g/dl), and albumin
levels (3.16  0.77 vs. 3.0  0.79 g/dl) were not signiﬁcantly different
between the HIV-monoinfected and HIV–HCV-co-infected groups.
All patients experienced signiﬁcant increases in CD4 cell counts
at 6 and 12 months after HAART initiation compared to baseline(p < 0.01 for all comparisons). The increase in CD4 cell counts was
signiﬁcant regardless of the HCV infection status.
Signiﬁcant increases in albumin levels (0.49  0.08 and
0.53  0.09 g/dl at 6 and 12 months, respectively; p < 0.05 for both
comparisons) and reductions in total protein (0.03  0.12 and
0.26  0.13 g/dl at 6 and 12 months, respectively; p < 0.01 at 12
months; not signiﬁcant at 6 months) were observed for the whole
group. Consequently, there was a concomitant signiﬁcant decrease in
the calculated globulin levels (0.50  0.09 and 0.76  0.11 g/dl at 6
and 12 months, respectively; p < 0.001 for both comparisons). In
addition, we observed a signiﬁcant increase in the proportion of
patients with normal albumin and protein levels as well as normal
albumin/globulin ratio at 12 months after starting HAART. Despite
these changes, only 43% of patients achieved a normal albumin/
globulin ratio 1 year after HAART (Fig. 1). Longer follow-up was
available for a subset of patients. After 2 and 3 years of HAART, the
proportion of patients achieving a normal albumin/globulin ratio
increased to 53% (32 of 60 patients) and 65% (32 of 49 patients),
respectively.
When patients were stratiﬁed by HCV infection status, HIV-
monoinfected patients had signiﬁcant improved changes in
albumin, total protein, and calculated globulin levels, with a
higher proportion of patients showing normal levels at 6 and 12
months after starting HAART (p < 0.01). In contrast, HIV–HCV-co-
infected patients showed a signiﬁcant increase only in albumin
levels (Fig. 1).
We did not observe any signiﬁcant correlations between
increases in CD4 cell counts and changes in total protein, albumin,
or calculated globulin levels.
5. Discussion
In this group of patients started onHAART andwith a viral load
<400 RNA copies/ml at 1 year after starting antiretroviral therapy
and for at least 6 months, we observed a signiﬁcant reduction in
total protein levels, a signiﬁcant increase in albumin levels, and a
reduction in calculated globulin levels. Despite these improved
parameters, an abnormal albumin/globulin ratio persisted in
more than half the patients for longer than 1 year after starting
HAART. Chronic HIV infection induces hypergammaglobulinemia
via polyclonal B-cell activation and spontaneous secretion of
immunoglobulins by abnormally activated B-cells.2 But, as an
expression of the aberrant immune activation that characterizes
untreated HIV infection,9–11 other globulin fractions are also
abnormally elevated among HIV-infected patients. The fact that
we studied calculated and not measured globulins is a limitation
of our study. In addition, other constituents of the globulin
fraction, like alpha or beta globulins rather than gamma globulins
(immunoglobulins), could also have decreased after HAART, thus
contributing to the observed ﬁnding of decreased total globulin
levels.With our study design, we cannot assess which component
of the globulin fraction is contributing the most to the observed
HAART-induced changes.
Cross-sectional studies that have evaluated the effect of HAART
speciﬁcally on IgG levels as a marker of B-cell dysfunction have
shown reduction in IgG levels among HIV-infected patients on
HAART compared to those not on HAART;4,5,12 however, as in our
study, abnormally elevated levels persisted after more than 12
months of complete viral suppression and changes in IgG levels
were not signiﬁcantly correlated to CD4 cell count.4,5,13 In a
longitudinal study of patients started on HAART, Morris et al.14
showed that the decrease in serum IgG levels among patients
achieving suppressed viremia lagged behind the reduction in
circulating IgG antibody-secreting cells, which was observed
within a few weeks after the start of therapy; nevertheless, after
32–36 weeks of HAART, plasma IgG concentrations were reduced
Fig. 1.Mean ( standard error (SE)) total protein (blue), albumin (orange), and calculated globulin (green) levels (panels A, B, and C) and percentage of patients with normal protein
levels (blue), normal albumin levels (orange), and normal albumin/protein ratio (green) (panels D, E, and F) for treatment-naı¨ve HIV-infected patients 6 months and 1 year after
starting HAART and with viral load <400 RNA copies/ml for at least 6 months at the 1-year evaluation. Panels A and D show data for the whole group (n = 75); B and E for the HIV-
monoinfected (n = 59) group; and C and F for the HIV–HCV-co-infected (n = 16) group. *p < 0.05.
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be hypergammaglobulinemic.
Among our patients co-infected with HCV, a higher proportion
of patients continued to have elevated protein and calculated
globulin levels when compared to the HIV-monoinfected. Serum
gamma globulin elevation in associationwith chronic hepatitis C is
a well-known phenomenon,15,16 and an additional effect of HCV
infection on serum IgG levels beyond that induced byHIV alone has
previously been described.4,13 However, Jacobson et al.4 found that
after adjustment for HCV co-infection, the effect of HAART in
decreasing IgG levels persisted. Both HIV and HCV infection affect
the B-cell compartment, and the immunologic dynamics of
antiretroviral treatment and suppressed HIV-1 replication on
normalization of B-cell function parameters (such as B-cell count
and immunoglobulin levels) may differ among HIV–HCV-co-infected patients compared to the HIV-monoinfected ones.13
Among our patients, albumin levels signiﬁcantly improved in
bothmonoinfected and co-infected patients, possibly secondary to
improved overall health status with HAART, and suggesting that
this abnormality is driven by both uncontrolled HIV infection as
well as by HCV-induced liver disease among co-infected subjects.
HAART-induced improvement in immune function, including
B-cell count and function,1,2 has translated clinically into a
decreased incidence of diseases associated with impaired humoral
responses, such as pneumococcal pneumonia,8,17 and with
improved responses to immunizations.17–19 It is recommended
that in patients with a CD4 cell count <200/mm3, immunization
should be deferred until immune reconstitution (deﬁned as >200
CD4 cells/mm3) has been achieved with HAART.20 Several studies
have demonstrated that patients with controlled viremia have
J. Serpa et al. / International Journal of Infectious Diseases 14S (2010) e41–e44e44improved responses to immunizations;18,19 one study speciﬁcally
showed that controlled viremia had an effect independent of CD4
cell count on the effectiveness of pneumococcal immunization.8
These observations suggest that factors besides CD4 cell count are
impacting humoral responses among HIV-infected patients, and
other laboratory parameters, such as viral load and markers of B-
cell function are necessary in the decision-making process for best
timing of immunization. Unfortunately, in clinical practice, we lack
a readily available tool to measure B-cell reconstitution. B-cell
count, an indicator of quantitative B-cell reconstitution but not
necessarily of function, can be determined by ﬂow cytometry at the
time of performing determination of T-cell subpopulations;
however, this assay is not routinely utilized in clinical practice.
Other laboratory studies, such as quantiﬁcation of immunoglobu-
lin levels and/or of soluble or cell-associated markers of B-cell
activation could also be used in the evaluation of B-cell
function.11,21–23
Given the importance of humoral immune reconstitution inHIV
after HAART and its lack of correlationwith the recovery of CD4 cell
counts, clinical studies to evaluate the use of surrogate markers of
B-cell function with speciﬁc outcomes, such as responses to
immunizations and rates of infections associated with impaired
humoral immunity, are warranted. Those studies should evaluate
the performance of surrogate markers of B-cell function that could
be used in resource-limited settings (such as calculated globulin
levels and albumin/globulin ratios) to the performance of themore
speciﬁc ones.
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